Wyeth Nutritionals: Pfizer’s New MVP, Or Benchwarmer?
This article was originally published in The Tan Sheet
Executive Summary
Wyeth Nutrition could boost Pfizer's revenue outside the U.S. and buffer some upcoming patent losses in its prescription roster through the pending $68 billion deal
You may also be interested in...
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Pfizer will appoint Wyeth's consumer health president to manage its new Diversified Businesses group, which will include consumer, nutritional and animal health, as part of a reorganization following the companies' planned merger
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Pfizer will appoint Wyeth's consumer health president to manage its new Diversified Businesses group, which will include consumer, nutritional and animal health, as part of a reorganization following the companies' planned merger
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Pfizer will appoint Wyeth's consumer health president to manage its new Diversified Businesses group, which will include consumer, nutritional and animal health, as part of a reorganization following the companies' planned merger